Iscador Qu for chronic hepatitis C: an exploratory study [abstract]

Abstract

Five patients with chronic hepatitis C were treated for one year with the herbal immunomodulatory agent Iscador (Weleda, Schwäbisch Gmünd Germany). Two patients showed 6–20 fold decreases in viral load and normalisation of liver inflammation. The treatment was well tolerated; no serious side effects were observed. The quality of life improved on average. Iscador may have potential as a non toxic therapy for chronic hepatitis C treatment.

Citation: Tusenius, K. J., Spoek, J. M., & Kramers, C. W. (2001). Iscador Qu for chronic hepatitis C: An exploratory study. Complementary Therapies in Medicine, 9(1), 12–16. https://doi.org/10.1054/ctim.2000.0408

[not open access]